Imatinib mesylate and Constipation - a phase IV clinical study of FDA data

Summary:

Constipation is reported as a side effect among people who take Imatinib mesylate (imatinib mesylate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Tasigna, and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Constipation when taking Imatinib mesylate. It is created by eHealthMe based on reports of 4,127 people who have side effects when taking Imatinib mesylate from the FDA, and is updated regularly.

What is Imatinib mesylate?

Imatinib mesylate has active ingredients of imatinib mesylate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 4,178 Imatinib mesylate users. Check the latest studies of Imatinib mesylate.

What is Constipation?

Constipation is found to be associated with 3,004 drugs and 4,619 conditions by eHealthMe. Check the latest studies of Constipation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 27, 2026

4,127 people reported to have side effects when taking Imatinib mesylate.
Among them, 51 people (1.24%) have Constipation.

Could Imatinib mesylate cause Constipation?

Among these 51 people:

How long have people been on Imatinib mesylate when they have Constipation? *

What is the gender of people who have Constipation when taking Imatinib mesylate? *

female: 38 %
male: 62 %

What is the age of people who have Constipation when taking Imatinib mesylate? *

What are other drugs people take besides Imatinib mesylate? *

What are other side effects people have besides Constipation? *

Nausea (feeling of having an urge to vomit): 18 people, 35.29%
Abdominal Pain: 14 people, 27.45%
Nausea And Vomiting: 14 people, 27.45%
Fever: 13 people, 25.49%
Diarrhea: 12 people, 23.53%
Abdominal Pain Upper: 11 people, 21.57%
Intestinal Obstruction: 10 people, 19.61%
Fatigue (feeling of tiredness): 9 people, 17.65%
Neoplasm Malignant (cancer tumour): 8 people, 15.69%
Hypophagia (reduced food intake): 8 people, 15.69%

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 21 people, 41.18%
Indigestion: 12 people, 23.53%
Gastrointestinal Stromal Tumor: 10 people, 19.61%
Nausea (feeling of having an urge to vomit): 8 people, 15.69%
Pain: 8 people, 15.69%
High Blood Pressure: 4 people, 7.84%
Oesophageal Adenocarcinoma (a cancer tumour of an epithelium in oesophagus): 4 people, 7.84%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 3.92%
Abdominal Discomfort: 2 people, 3.92%
Neuropathy Peripheral (surface nerve damage): 1 person, 1.96%

* Approximation only. Some reports may have incomplete information.

Do you take Imatinib mesylate and have Constipation?

- Check whether Constipation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Imatinib mesylate:

Imatinib mesylate (4,178 reports)

Constipation treatments and more:

Constipation (337,881 reports)

Browse all side effects of Imatinib mesylate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Constipation:

Constipation (3,004 drugs)

Browse all the conditions that are associated with Constipation:

Constipation (4,619 conditions)

Related publications that referenced our studies

O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .
O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on imatinib mesylate (the active ingredients of Imatinib mesylate) and Imatinib mesylate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.